Affimed Gmbh

Affimed Therapeutics, Ag

Amphivena Therapeutics, Inc.

University of the Witwatersrand, Johannesburg

Affemed Gmbh

Affirmed Gmbh

Ludwig-Maximilians-Universitat München

Stefan Knackmuss

Uwe Reusch

Melvyn Little

Ivica Fucek

Kristina Ellwanger

Michael Weichel

Erich Rajkovic

Eugene Zhukovsky

Vera Molkenthin

Luke Evnin

Jeanmarie Guenot

Martin Treder

Fabrice Le Gall

Lori Kunkel

Judith A Fox

Karin Hoffmann

Claudia Wall

Karlheinz Peter

Sergey Kipriyanov

Peter Röttgen

Thorsten Ross

Peter Roettgen

Meike Schwarz

Stefan Franz Thomas Weiss

Marc Saul Weinberg

Claudia Büttner

Katarina Jovanovic

Clémence Rey

Claudia Buettner

Vera Mick

Claudia Linhard

Bianca Da Costa Dias

Danielle Gonsavles

Fionnuala McAleese-Eser

Markus Eser

Jens-Peter Marschner

Fionnuala Mcaleese-Eser

Eugene Zhukovksy

Stefan Weiss

The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.

Tandem diabody for CD16A-directed NK-cell engagement

Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.

Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33cancers, diseases and conditions such as acute myeloid leukemia (AML).

Bispecific CD33 and CD3 binding proteins

This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.

Antibody binding sites specific for EGFRvIII

The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.

CD3 binding domains

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc&#x3b3;RIIIA), and in particular binding molecules that specifically bind the A form Fc&#x3b3;RIII but do not bind to the B form of Fc&#x3b3;RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

Anti-CD16 binding molecules

The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (&#x3b2;) and gamma (&#x3b3;) secretases and amyloid beta peptide (A&#x3b2;), and also relates to a method of reducing A&#x3b2; shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.

Compounds for use in the treatment of Alzheimer's disease

The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.

Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa

Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.

Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types

Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa

Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.

Single-chain antibody acting against 37 kDa/67 kDa Iaminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof

Growing community of inventors

Plankstadt, Germany

Stefan Knackmuss